Associate Professor Martin Weltman is a Conjoint Associate Professor of Medicine in the Nepean Clinical School at the University of Sydney's Sydney Medical School. He earned his MBBCh from the University of the Witwatersrand in South Africa in 1983, followed by specialist training in South Africa and Australia at Royal Hobart Hospital, St George Hospital, and Westmead Hospital, obtaining Fellowship of the Royal Australasian College of Physicians (FRACP) in 1992. He completed a PhD from the University of Sydney in 1998, focusing on fatty liver disease. Currently, he serves as Head of the Department of Gastroenterology and Hepatology at Nepean Hospital, where he is a Staff Specialist, and maintains consulting practices in Bondi Junction with admitting rights at Prince of Wales Private Hospital, Nepean Public Hospital, and Nepean Private Hospital. He performs endoscopic procedures at Double Bay Day Hospital, Prince of Wales Private Hospital, and Nepean Public and Private Hospitals. Weltman leads the Nepean Gastroenterology Research group, which conducts clinical trials locally and internationally on inflammatory bowel diseases, hepatitis C, primary biliary cirrhosis, non-alcoholic steatohepatitis, liver disease, liver cancer, dyspepsia, and chronic constipation.

His research interests encompass liver disorders including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune liver diseases, viral hepatitis, hepatocellular carcinoma, capsule endoscopy, reflux oesophagitis, colon cancer screening, and inflammatory bowel disease. Weltman has authored over 200 peer-reviewed publications, multiple book chapters, and co-edited the textbook Gastroenterology and Hepatology: A Clinical Handbook. He serves as an editor and reviewer for specialist medical journals in gastroenterology. Notable recent publications include 'Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial' (Nature Medicine, 2025), 'Surviving Hepatitis C—Understanding Death and Survival Beyond Cure' (2025), and 'Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C study' (2025). His work has garnered over 12,000 citations, contributing significantly to clinical outcomes in metabolic and viral liver diseases.

Professional Email: martin.weltman@sydney.edu.au